From the Literature
Inotuzumab Ozogamicin Shows High Response Rate in Refractory/Relapsed ALL
Background: Patients with refractory or relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis. Inotuzumab ozogamicin is a monoclonal antibody against CD22, which is highly expressed on the surface of leukemic cells in patients with ALL. Studies with other monoclonal antibodies against CD22 or other surface antigens have shown encouraging activity in patients with ALL.
Background: For women with advanced ovarian cancer, surgery and platinum-based chemotherapy are the standard treatment, but the prognosis is poor. Angiogenesis is involved in ovarian cancer. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, has shown tumor response and delayed progression in women with ovarian cancer in early clinical trials. Two new, phase 3 studies have examined its effect on progression-free survival (PFS) and overall survival (OS) in women with advanced ovarian cancer.
Background: Although trastuzumab, an HER2 inhibitor that binds to subdomain IV of the HER2 extracellular growth domain, is effective in inhibiting tumor growth in HER2-positive metastatic breast cancer, the disease often progresses after therapy. Pertuzumab, which binds to subdomain II of the growth domain, offers a complementary mechanism of action that, in combination with that of trastuzumab, enhances the blockade of HER2 signaling and potentially produces greater antitumor activity, as has been demonstrated in phase 2 studies.
Background: Women with breast cancer often complain of cognitive difficulties after chemotherapy. Findings from several cross-sectional and longitudinal studies of women who receive chemotherapy for breast cancer have confirmed a correlation between impaired memory and other cognitive functions and chemotherapy. This study investigated the link between chemotherapy-induced structural changes in the brain and cognitive function.
Background: As many as 15% to 30% of patients who receive BRAF inhibitors, such as vemurafenib or dabrafenib, for metastatic melanoma develop cutaneous squamous-cell carcinomas and keratoacanthomas (nonmelanoma skin cancer) during their therapy. A new study investigated the nature of the oncogenic mutations in patients with the BRAF V600 mutation who received vemurafenib.
Background: In previous studies, the addition of bevacizumab to first-line chemotherapy regimens in the treatment of metastatic cancer led to modest improvements in ORR and PFS. Now 2 separate studies have investigated the efficacy of adding the VEGF inhibitor bevacizumab to adjuvant chemotherapy regimens in patients with early-stage breast cancer.
Exemestane Effective for the Prevention of Invasive Breast Cancer in Postmenopausal Women
Results 21 - 30 of 31